James B. Breitmeyer, Chief Executive Officer at Oncternal Therapeutics, Inc. (ONCT), bought 150,000 shares at $0.29 ($44K) on 2023-04-13, disclosed to the SEC on 2023-04-17.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.29 | 100,000 | $29K | 65.9% |
| 2 | $0.29 | 2,250 | $653 | 1.5% |
| 3 | $0.30 | 47,750 | $14K | 32.6% |
| Total | $0.29 avg | 150,000 | $44K | 100% |
| Filing → |
| ZGNX | SELL | 2019-11-27 | $250K | — | Filing → |
| CADX | SELL | 2011-11-04 | $71K | — | Filing → |
| CADX | SELL | 2011-07-12 | $27K | — | Filing → |